Updated time: 2020-09-01 17:23:23
12A-1090601
2020-09-01
US provisional filing
The COVID-19 pandemic has been causing devastating damage worldwide. Currently, there are no effective strategies to fight against SARS-CoV-2 infection. Here we developed a humanized decoy antibody (ACE2-Fc fusion protein) that targets the SARS-CoV-2 Spike protein. In addition, the peptidase activity also enables ACE2-Fc to reduce angiotensin II mediated cytokine cascade. Using real virus from clinical isolates, we demonstrate that ACE2-Fc fusion protein can abrogate virus replication by blocking of SARS-CoV-2 entry. We expect that this decoy antibody can help patients to against SARS-CoV-2.
- ACE2-Fc fusion protein can form dimer mimic a humanized antibody and specifically binds to SARS-CoV-2 Spike protein.
- ACE2-Fc fusion protein abrogates virus replication by blocking of SARS-CoV-2 entry in clinical isolates.
- The peptidase activity of ACE2-Fc fusion protein may enable the decoy antibody to reduce angiotensin II mediated cytokine cascade.
- The ACE2 and Fc are self-antigens, which will not induce auto-immune response.
- We expect the safety and specificity of ACE2-Fc are better than other monoclonal antibody.
- ACE2-Fc blocks SARS-CoV-2 entry and infection.
- ACE2-Fc prevents SARS-CoV-2 infection.
- ACE2-Fc reduces the inflammation mediated by SARS-CoV-2 infection.
- ACE2-Fc triggers antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) for clearance of SARS-CoV-2 and infected Host cells.
Pan-Chyr Yang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

ACE2-Fc, decoy antibody blocks SARS-CoV-2 entry and infection